title: Chemotherapy of breast cancer in the elderly.
abstract: Breast cancer arises in about 48% of patients older than 65 years and more than 30% occurs in those over 70 years being the leading cause of cancer-related death in women older than 65. Elderly patients tolerate chemotherapy poorly compared to their younger counterpart because of progressive reduction of organ function and comorbidities related to age. For this reason, the elderly have been excluded from or underrepresented in most cancer studies and, in clinical practice, they often receive inadequate and untested treatments. For adjuvant chemotherapy, a low percentage of patients over 70 years of age were included in few trials and always in a proportion much lower than the prevalence of cancer in that age group. Adjuvant chemotherapy, preferably including an anthracycline especially in patients with HER-2/neu-positive tumours, seems to be beneficial in older women who have substantial risk of dying of breast cancer. To date even if there is no specifically randomised study, single-agent chemotherapy probably might be considered a reasonable treatment for advanced breast cancer in the elderly. One of the actual main field of clinical research in the treatment of breast cancer is the role of targeted therapies. Chronologic age is a risk factor for toxicities such as myelosuppression and mucositis, and older patients may require more supportive care. In order to plan medical treatment in breast cancer elderly patients is mandatory to practice a comprehensive geriatric assessment that includes evaluation of comorbidities, functional dependence, socio-economic, emotional and cognitive conditions, an estimate of life expectancy and recognition of frailty. The authors review the literature regarding age-specific chemotherapeutic issues in the management of breast cancer elderly patients.
authors.affiliation: U.O. Oncologia Medica, Azienda Ospedaliera S.G. Moscati, Avellino, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Rossi
authors.forename: G
authors.initials: G
authors.lastname: Colantuoni
authors.forename: P
authors.initials: P
authors.lastname: Maione
authors.forename: C
authors.initials: C
authors.lastname: Ferrara
authors.forename: G
authors.initials: G
authors.lastname: Airoma
authors.forename: M L
authors.initials: ML
authors.lastname: Barzelloni
authors.forename: V
authors.initials: V
authors.lastname: Castaldo
authors.forename: C
authors.initials: C
authors.lastname: Gridelli
mesh_terms: D000368:Aged; D000375:Aging; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D015897:Comorbidity; D004347:Drug Interactions; D016330:Frail Elderly; D006801:Humans; D016032:Randomized Controlled Trials as Topic
chemical_list: D000970:Antineoplastic Agents